Tekla Life Sciences Inves... (HQL)
NYSE: HQL
· Real-Time Price · USD
16.46
0.25 (1.54%)
At close: Oct 15, 2025, 3:59 PM
16.45
-0.06%
After-hours: Oct 15, 2025, 06:21 PM EDT
Tekla Life Sciences Investors Balance Sheet Statement
Financials in USD. Fiscal
year is
October - September.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 |
Cash & Equivalents | n/a | 477.00 | 445.00 | 990.00 |
Short-Term Investments | 17.23M | 15.24M | 32.94M | 17.17M |
Cash & Short-Term Investments | n/a | 15.24M | 445.00 | 990.00 |
Receivables | 231.11K | 5.04M | 623.47K | 150.34K |
Accounts Receivables | 231.11K | 5.04M | 623.47K | 150.34K |
Other Receivables | n/a | n/a | n/a | n/a |
Inventory | n/a | 20.29M | n/a | n/a |
Prepaid Expenses | 41.53K | -15.24M | 25.18K | 26.3K |
Other Current Assets | 8.97K | -20.29M | -25.18K | -32.97K |
Total Current Assets | 281.61K | 5.05M | 623.92K | 144.66K |
Property-Plant & Equipment | n/a | n/a | n/a | n/a |
Goodwill | n/a | n/a | n/a | n/a |
Intangible Assets | n/a | n/a | n/a | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a |
Long-Term Investments | 460.3M | 397.53M | 414.08M | 534.01M |
Tax Assets | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 13.9M | n/a | n/a | n/a |
Total Long-Term Assets | 474.2M | 397.53M | 414.08M | 534.01M |
Other Assets | -13.9M | 26.28K | 25.36K | 32.97K |
Total Assets | 460.58M | 402.6M | 414.73M | 534.19M |
Total Payables | 1.79K | n/a | 5.1M | 8.7M |
Account Payables | 1.79K | n/a | 5.1M | 150.34K |
Other Payables | n/a | n/a | n/a | n/a |
Accrued Expenses | 836.01K | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | 11.09M | 10.04M |
Current Capital Lease Obligations | n/a | n/a | n/a | n/a |
Tax Payables | n/a | n/a | n/a | n/a |
Deferred Revenue | n/a | n/a | 5.09M | n/a |
Other Current Liabilities | 50.81K | n/a | -16.18M | -8M |
Total Current Liabilities | 888.61K | n/a | 5.1M | 10.75M |
Long-Term Debt | n/a | n/a | n/a | n/a |
Non-Current Capital Lease Obligations | n/a | n/a | n/a | n/a |
Non-Current Deferred Revenue | n/a | n/a | n/a | n/a |
Non-Current Deferred Tax Liabilities | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 886.82K | 666.96K | 11.72M | 10.75M |
Total Long-Term Liabilities | 886.82K | 666.96K | 11.72M | 10.75M |
Other Liabilities | 888.61K | 666.96K | 6.62M | -9.4M |
Capital Lease Obligations | n/a | n/a | n/a | 1.34M |
Total Liabilities | 888.61K | 666.96K | 16.82M | 10.75M |
Treasury Stock | n/a | n/a | n/a | n/a |
Preferred Stock | n/a | n/a | n/a | n/a |
Common Stock | 280.61K | 267.91K | 256.8K | 246.68K |
Retained Earnings | 44.13M | -1.48M | 9.55M | 150.7M |
Additional Paid-In Capital | 415.29M | 403.15M | 388.1M | 372.49M |
Comprehensive Income | n/a | n/a | n/a | n/a |
Other Stockholders Equity | n/a | n/a | n/a | n/a |
Shareholders Equity | 459.69M | 401.93M | 397.9M | 523.44M |
Total Equity | 459.69M | 401.93M | 397.9M | 523.44M |
Minority Interest | n/a | n/a | n/a | n/a |
Total Liabilities & Equity | 460.58M | 402.6M | 414.73M | 534.19M |
Total Investments | 460.3M | 397.53M | 414.08M | 534.01M |
Total Debt | n/a | n/a | 11.09M | 1.34M |
Net Debt | n/a | -477 | 10.65K | 1.34M |
Book Value | 459.69M | 401.93M | 397.9M | 523.44M |
Book Value Per Share | 16.38 | 14.21 | 15.49 | 21.58 |
Source: Financial Modeling Prep. Financial Sources.